GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinew Pharma Inc (ROCO:6634) » Definitions » ROC %

Sinew Pharma (ROCO:6634) ROC % : -224.11% (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Sinew Pharma ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Sinew Pharma's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was -224.11%.

As of today (2024-12-12), Sinew Pharma's WACC % is 3.47%. Sinew Pharma's ROC % is -112.05% (calculated using TTM income statement data). Sinew Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Sinew Pharma ROC % Historical Data

The historical data trend for Sinew Pharma's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinew Pharma ROC % Chart

Sinew Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC %
Get a 7-Day Free Trial Premium Member Only -60.22 -32.73 -36.90 -97.74 -172.06

Sinew Pharma Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Jun24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.87 -145.53 -193.76 -173.51 -224.11

Sinew Pharma ROC % Calculation

Sinew Pharma's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-148.428 * ( 1 - 0% )/( (89.379 + 83.151)/ 2 )
=-148.428/86.265
=-172.06 %

where

Invested Capital(A: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1584.759 - 12.719 - ( 1482.661 - max(0, 15.109 - 1501.181+1482.661))
=89.379

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1487.161 - 19.168 - ( 1391.167 - max(0, 23.25 - 1408.092+1391.167))
=83.151

Sinew Pharma's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-167.036 * ( 1 - 0% )/( (84.902 + 64.167)/ 2 )
=-167.036/74.5345
=-224.11 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1439.545 - 14.418 - ( 1341.945 - max(0, 21.806 - 1362.031+1341.945))
=84.902

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1293.287 - 20.314 - ( 1212.657 - max(0, 27.825 - 1236.631+1212.657))
=64.167

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinew Pharma  (ROCO:6634) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sinew Pharma's WACC % is 3.47%. Sinew Pharma's ROC % is -112.05% (calculated using TTM income statement data). Sinew Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Sinew Pharma ROC % Related Terms

Thank you for viewing the detailed overview of Sinew Pharma's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinew Pharma Business Description

Traded in Other Exchanges
N/A
Address
C516, Building C, Number 99, Lane 130, Section 1, Xueyin Road, Nangang District, Taipei, TWN, 11571
Sinew Pharma Inc is a Taiwan-based biopharmaceutical company. The company is mainly engaged in the research and development of new drugs for the treatment of liver diseases and pain relief. Its drug candidates includes SNP-610, SNP-630, SNP-810, SNP-820, SNP-830 and SNP-840.

Sinew Pharma Headlines

No Headlines